In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

about

Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis.

P2860

Q39269795-4C9B0E2F-FF58-4B35-912F-0F2CAAA255F0

P2860

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

Item

http://www.wikidata.org/entity/Q40936437

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

@en

type

Item

label

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

@en

prefLabel

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

@en

P1476

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

@en

P2093

Adela Martin-Vicente

http://www.w3.org/2001/XMLSchema#string

P2860

MEGA6: Molecular Evolutionary Genetics Analysis version 6.0

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus

Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillu

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis

Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification.

The role of murine models in the development of antifungal therapy for systemic mycoses.

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy

P304

296-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01462-15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Javier Capilla

Josep Guarro

Adela Martin-Vicente

P577

2015-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26503653

http://www.w3.org/2001/XMLSchema#string

P921

aspergillosis

P932

4704177

http://www.w3.org/2001/XMLSchema#string

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

about

P2860

P2860

In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932